On Wednesday, Neuralink, the brain-computer interface company founded by Elon Musk, announced that it has secured approval to initiate its inaugural clinical trial in Canada. The trial will focus on a device that enables individuals with paralysis to operate digital devices through thought alone.
A brain chip startup has announced that a Canadian study is set to evaluate its implant’s safety and preliminary functionality. This innovative technology allows individuals with quadriplegia, characterised by paralysis of all four limbs, to operate external devices using their thoughts.
Canada’s University Health Network hospital said in a separate statement that its Toronto facility had been selected to perform the complex neurosurgical procedure.
Health Canada, the regulatory body, has yet to respond to the request for comment.
Neuralink has successfully conducted implant procedures on two patients in the United States. The company reports positive results from the second trial patient, who has been utilising the device for video gaming and acquiring skills in 3D object design.
Established in 2016 by Elon Musk alongside a team of engineers, Neuralink is developing a brain chip interface designed for implantation within the skull. The company claims this technology could ultimately assist disabled patients in regaining mobility and communication abilities and restoring vision.
In September, the startup was granted the “breakthrough device” designation by the U.S. Food and Drug Administration for its innovative implant designed to restore vision.
